

Samuel H. Pepkowitz, MD, Medical Director
 345 Oyster Point Blvd
 South San Francisco, CA 94080 - Tel: (800) 777-0177

Patient Name	DOB	Patient ID/Medical Record #	Gender	Monogram Accession #
Date Collected	Date Received	Date Reported	Mode	Report Status
Referring Physician			Reference Lab ID/Order #	
Comments			HIV-1 Subtype: B	

	Generic Name	Brand Name	Assessment	Drug Resistance Associated Mutations Detected	Comments
NRTI	Abacavir	Ziagen	Sensitive	D67N, M184I/V	
	Didanosine	Videx	Resistant	D67N, M184I/V	
	Emtricitabine	Emtriva	Resistant	D67N, M184I/V	
	Lamivudine	Epivir	Resistant	D67N, M184I/V	
	Stavudine	Zerit	Sensitive	D67N	
	Tenofovir	Viread	Sensitive	D67N	
	Zidovudine	Retrovir	Sensitive	D67N	
NNRTI	Efavirenz	Sustiva	Resistant	K103N, K238T	
	Etravirine	Intelence	Sensitive	K238T	
	Nevirapine	Viramune	Resistant	K103N, K238T	
	Rilpivirine	Edurant	Sensitive	K238T	
INI	Dolutegravir	Tivicay	Sensitive	T97A, Y143R	
	Elvitegravir	Elvitegravir	Resistant	T97A, Y143R	
	Raltegravir	Isentress	Resistant	T97A, Y143R	
PI	Atazanavir	Reyataz	Resistance Possible	K20I, E35D, M36I, L90M	
		Reyataz / r†	Sensitive	K20I, E35D, M36I, L90M	
	Darunavir	Prezista / r†	Sensitive	L90M	
	Fosamprenavir	Lexiva / r†	Sensitive	E35D, L90M	
	Indinavir	Crixivan / r†	Sensitive	K20I, M36I, A71T, L90M	
	Lopinavir	Kaletra†	Sensitive	K20I, A71T, L90M	
	Nelfinavir	Viracept	Resistant	K20I, E35D, M36I, A71T, L90M	
	Ritonavir	Norvir	Resistance Possible	E35D, A71T, L90M	
	Saquinavir	Invirase / r†	Resistance Possible	K20I, E35D, A71T, L90M	
	Tipranavir	Aptivus / r†	Sensitive	I13V, E35D, M36I, L90M	

Samuel H. Pepkowitz, MD, Medical Director
 345 Oyster Point Blvd
 South San Francisco, CA 94080 - Tel: (800) 777-0177

Patient Name	DOB	Patient ID/Medical Record #	Gender	Monogram Accession #
Date Collected	Date Received	Date Reported	Mode	Report Status

- * Assessment of drug susceptibility is based upon detected mutations and interpreted using an advanced proprietary algorithm (version 16).
- † Interpretation algorithms for ritonavir-boosted protease inhibitors appropriate for the following dosages: AMP/r 600mg/100mg BID; ATV/r 300mg/100mg QD; IDV/r 800mg/200mg BID; LPV/r 400mg/100mg BID; SQV/r 1000mg/100mg BID; TPV/r 500mg/200mg BID; and DRV/r 600mg/100mg BID.
- * **Mixtures** are indicated by amino acids separated by a slash. Deletions in the amino acid sequence are indicated by a ^ symbol.

NRTI	D 67 N	M 184 I V				
NNRTI	K 103 N	K 238 T				
PI	I 13 V	K 20 I	E 35 D	M 36 I	A 71 T	L 90 M
IN	T 97 A	Y 143 R				

Summary of Mutations Observed

RT	K32Q, V35I, D67N, Q102K, K103N, I135R, C162S, Q174K, I178M, M184I/V, Q207E, R211K, K238T, V245T, A272P, T286A, V293I, E297K, Q334Y, R356K, M357V, K358R, G359S, D364N
IN	V31I, V72I, T97A, L101I, V113I, S119S/T, T124A, E138D, Y143R, E157E/Q, K188R, G193E, V201I, V234L, D288N
PR	I13V, I15V, Q18K, K20I, E35D, M36I, N37E, L63P, A71T, V77I, L90M, I93L

For more information on interpreting this report, please visit www.MonogramBio.com or call Customer Service at 800-777-0177 between the hours of 6:30am to 5:00pm PT Monday through Friday.

GenoSure Archive is a DNA sequencing assay that uses next-generation sequencing to analyze the protease (amino acids 1-99), reverse transcriptase (amino acids 1-400) and integrase (amino acids 1-288) coding regions derived from HIV-1 cell associated DNA. Subtype is determined using the protease and reverse transcriptase sequence information. This assay meets the standards for performance characteristics and all other quality control and assurance requirements established by the Clinical Laboratory Improvement Amendments. The results have been disclosed to you from confidential records protected by law and are not to be disclosed to unauthorized persons. Further disclosure of these results is prohibited without specific consent of the persons to whom it pertains, or as permitted by law.